NGM Biopharmaceuticals is a company that makes medicine. Another group called The Column Group wants to buy all the parts of this company. This means they want to own it completely and make decisions for it. The company has made a special team to think about this idea and other ways to make their business better. Because of this news, people are buying more shares of NGM Biopharmaceuticals, so the price is going up. Read from source...

1. The headline is misleading and sensationalized. It suggests that NGM Biopharmaceuticals stock is blasting higher because of a specific event (the EOI from The Column Group), when in reality, the stock price may be influenced by many other factors such as market sentiment, news, rumors, etc.
2. The article does not provide any evidence or details about the EOI, such as the offer price, the terms and conditions, the timeline, the rationale behind the acquisition, etc. It only mentions that it is a non-binding expression of interest, which means that there is no guarantee that the deal will materialize.
3. The article does not mention any potential conflicts of interest or conflicts of loyalty that may arise from The Column Group's proposal, such as its relationship with NGM Biopharmaceuticals, its shareholding, its business model, etc. It also does not disclose the identity and background of the special committee formed by NGM Biopharmaceuticals to evaluate the EOI.
4. The article implies that taking the company private would be beneficial for NGM Biopharmaceuticals' shareholders, but it does not provide any supporting arguments or evidence for this claim. It also does not consider the potential drawbacks or risks of such a transaction, such as the loss of liquidity, the dilution of ownership, the increase in debt, the change in corporate governance, etc.
5. The article uses emotional language and phrases, such as "blasting higher", "potential acquisition", "special committee", which may appeal to the readers' emotions rather than their rationality. It also does not provide any objective or balanced analysis of the situation, but rather promotes a positive outlook for NGM Biopharmaceuticals and The Column Group.